General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Frequently asked questions

Novartis Shares

General Financial Questions

  • How do you calculate your earning per share?

    Per-share information1

    Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.


    2013
    Restated
    20121
    Basic earnings per share
    Weighted average number of shares outstanding (in millions)
    2,441 2,418
    Net income attributable to shareholders of Novartis AG (USD millions) 9,175 9,270
    Basic earnings per share (USD ) 3.76 3.83

    1. Restated to reflect the adoption of revised IAS19 on Employee Benefits (see Annual report 2013 Note 30).


    Novartis shares are widely held. As of December 31, 2013, Novartis had approximately 155 000 shareholders (2012: 161 000) listed in its share register, representing 73% of issued shares. Based on the Novartis AG share register and excluding treasury shares held by Novartis AG and its subsidiaries (excluding foundations), approximately 41% (2012: 42%) of the shares registered by name were held in Switzerland and 47% were held in the US (2012: 46%). Approximately 12% of the shares registered in the share register were held by individual investors, while 88% were held by legal entities, nominees, fiduciaries and the ADS depositary.

  • Are there any limitations on voting rights for registered shareholders?

    The Company’s Articles of Incorporation state that no person or entity shall be registered with the right to vote for more than 2% of the share capital as set forth in the Commercial Register. In particular cases the Board of Directors may allow exemptions fromthe limitation for registration in the share register.
    According to the share register, shareholders owning 2% or more of the Company’s capital at December 31, excluding treasury shares held by Novartis AG and other Novartis subsidiaries, are as follows:

    % holding of share capital
    December 31, 2013
    % holding of share capital
    December 31, 2012
    Novartis Foundation for Employee Participation, Basel 3.0 4.0
    Emasan AG, Basel 3.3 3.3

  • When does the fiscal year end for Novartis?

    Novartis uses the 12-month calendar year, ending December 31, as its fiscal year.

  • Where can I find historical financial information about Novartis?

    You can review quarterly and full-year historical financial information in the
    sales and results or event calendar sections.

  • What is the exposure to exchange rate risk for Novartis?

    Novartis transacts business in many currencies. As a result of the Group’s foreign currency exposure, exchange rate fluctuations have a significant impact on its income statement, in the form of both translation risk and transaction risk.

    Translation risk is the risk that the Group’s consolidated financial statements for a particular period may be affected by changes in the prevailing rates of the various currencies of the reporting subsidiaries.
    Transaction risk is the risk that the currency impact of transactions executed in currencies other than the subsidiary currency may vary according to currency fluctuations.

    Recent data for selected currencies is available in our Selected exchange rate data page.

  • What accounting convention does Novartis follow?

    The Novartis Group (Group or Novartis) consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared I accordance with the historical cost convention except for items that are required to be accounted for at fair value.

    The preparation of financial statements requires management to make certain estimates and assumptions either at the balance sheet date or during the year that affect the reported amounts of assets and liabilities (including any contingent amounts) as well as revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions.

  • How can I get a copy of your Annual Report?

    You will find detailed information about the 2013 Annual Report in our Annual Report page.

    You will find past annual reports in the order and download center of our newsroom.

Investor Relations Customer Services

For all other investor relations-related questions

Please contact us at investor relations contacts

For all other share registry-related questions

Please contact us at share registry contact

Stock chart